RESEARCHER PROFILE
Matthias Pinter
← Back to Medical University of Vienna
M
Medical University of Vienna
Matthias Pinter works in Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Liver Disease and Transplantation, Liver Disease Diagnosis and Treatment. Recorded institutional associations include Vienna General Hospital, Medical University of Vienna.
482Publications
12,402Citations
57H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
2021 · 1,280 citationsAtezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2023 · 536 citationsObesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy
2016 · 456 citationsNivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
2025 · 373 citationsThe ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma
2013 · 343 citationsCarvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
2012 · 342 citationsThe Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma
2020 · 339 citationsTargeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
2017 · 332 citationsPrognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
2021 · 303 citationsCancer and liver cirrhosis: implications on prognosis and management
2016 · 295 citationsPreliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
2022 · 235 citationsImmunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups
2020 · 233 citationsObesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2
2018 · 221 citationsSystemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality
2020 · 211 citationsAdvanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib
2012 · 197 citationsDeviations of the immune cell landscape between healthy liver and hepatocellular carcinoma
2018 · 190 citationsSorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
2009 · 178 citationsReview article: systemic treatment of hepatocellular carcinoma
2018 · 160 citationsChanges in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon‐Free Therapy
2019 · 160 citationsHow to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma
2014 · 159 citationsNivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
2024 · 151 citationsTargeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer
2017 · 138 citationsHCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
2021 · 135 citationsSingle determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma
2012 · 132 citationsImmune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
2023 · 132 citations
